Key result
Doxofylline maintains asthma and COPD efficacy without the direct CV stimulation of other bronchodilators.
Why the study?
The arrhythmogenic actions of bronchodilators may negatively impact survival in patients with respiratory diseases, necessitating evaluation of safer alternatives.
Does doxofylline provide bronchodilation without major cardiovascular adverse effects compared to other bronchodilators in patients with asthma or COPD?
Population
Patients with bronchial asthma or chronic obstructive pulmonary disease
Comparison
Doxofylline versus other bronchodilators such as theophylline
Design
Review of experimental and clinical studies
Authors
Loading...
May support doxofylline in asthma/COPD patients with CV risk; leaves open prospective trials to confirm safety.
Does doxofylline provide bronchodilation without major cardiovascular adverse effects compared to other bronchodilators in patients with asthma or COPD?
Doxofylline is a xanthine bronchodilator that offers efficacy in asthma and COPD without the arrhythmogenic cardiovascular adverse effects typically associated with this class of drugs.
Dini et al. (2001) conducted a review in Bronchial asthma or chronic obstructive pulmonary disease. Doxofylline vs. Other bronchodilators was evaluated. Doxofylline is a novel xanthine bronchodilator that demonstrates efficacy in asthma and COPD while being devoid of direct cardiovascular stimulatory effects compared to other bronchodilators.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: